[en] Aim: Compounds such ^99mTc-MDP and ^99mTc-HEDP are used regularly in bone scintigraphy for metastasis detection. The therapeutics properties of beta emitter radionuclides like ¹⁵³Sm, ¹⁶⁶Ho and ¹⁷⁷Lu has been widely reported in literature being ¹⁷⁷Lu the less developed for medical applications. With the purpose of study different radiopharmaceuticals alternatives, for metastasis bone palliation, we have evaluated, on a comparative basis, the labeling of ¹⁵³Sm-MDP, ¹⁵³Sm-HEDP, ¹⁶⁶Ho-MDP, ¹⁶⁶Ho-HEDP, ¹⁷⁷Lu-MDP and ¹⁷⁷Lu-HEDP from the exhibited radionuclidic purity and biological distribution point of view. Material and Methods: The radionuclides were produced at La Reina Research Reactor, Chilean Nuclear Energy Commission. The radionuclidic purity was determined by gamma-Ray spectrometry. The labeling was accomplished with MDP (Plenum) and HEDP synthesized in-house. The in-vitro affinity of labeled compounds to the mineral bone matrix was determined using hydroxyapatite (HA) as substrate. The radiochemical purity was measured by two procedures: an ionic exchange column, Sephadex G-25, eluted with 20 mL of NaCl 0.9% and thin layer chromatography ITLC-SG, using the ammonia:water (1:25) and ketone:water:hydrochloric acid (7:2:1) systems. All the biodistribution studies were performed on healthy rats (CF1) at 1, 3 and 24 h post-injection. Results: The totality of compounds under consideration shows a large bonding affinity for HA, with the exception of ¹⁷⁷Lu-HEDP which showed a somewhat lower bond degree (author)